Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

In the latest trading session, Moderna (MRNA) closed at $41.66, marking a +0.6% move from the previous day. The S&P 500 logs the best first week of a presidential term in four decades. Here are ...

University of Wisconsin–Madison researchers have developed a promising technique for treating osteoarthritis using ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

Russia cancer vaccine could receive approval by August allowing treatment to begin the head of the Gamaleya Research ...

Why? Researchers at Boston Children’s Hospital, led by Byron Brook, PhD, David Dowling, PhD, and Ofer Levy, MD, PhD, found some answers — while providing proof-of-concept of a new system that can ...

Scientists in the US say they have developed an mRNA-based vaccine that encompasses ... way to go from the animal model to humans. The type of response, the extent of the response, the persistence ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.